TTP (Thrombotic thrombocytopenic purpura), also called Moschcowitz syndrome, was first described in 1924.
It is a rare, life-threatening, disorder of the blood-coagulation system. It can cause thrombosis especially in the brain and in the kidneys.
- thrombocytopenia (bleeding tendency)
- haemolytic anaemia
- neurological symptoms (e.g. stroke, about 65%)
- drugs (e.g. Mitomycin C)
For further information please visit the website of the TTP support group.
-  Mitomicin C is a common cytostatic drug. It is widely used in the chemotherapy of many types of cancer, such as bladder, stomach, bowel, lung and breast cancer. TTP is listed as a "rare, but dangerous" side effect. Around 10% of the patients treated with MMC develop TTP during the first 5-10 months after the start of therapy (Dr. Hans-Peter Lipp in "Im Focus Onkologie" 5-2007).